Landow v. Wachovia Securities, LLC

966 F. Supp. 2d 106, 2013 WL 4432383, 2013 U.S. Dist. LEXIS 116149
CourtDistrict Court, E.D. New York
DecidedAugust 12, 2013
DocketNo. 12-CV-3277 (SJF)(AKT)
StatusPublished
Cited by15 cases

This text of 966 F. Supp. 2d 106 (Landow v. Wachovia Securities, LLC) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Landow v. Wachovia Securities, LLC, 966 F. Supp. 2d 106, 2013 WL 4432383, 2013 U.S. Dist. LEXIS 116149 (E.D.N.Y. 2013).

Opinion

ORDER

FEUERSTEIN, District Judge.

On June 29, 2012, plaintiff Jonathan Landow (“plaintiff’) commenced this action against defendants Wachovia Securities, LLC (“Wachovia”), Wells Fargo Ad-visors, LLC (“Wells Fargo”), Robert William Eddy (“Eddy”), George M. Gordon III (“Gordon”), Walter R. Anderson (“Anderson”) and Walter Randolph [111]*111Anderson, Jr. (“Anderson Jr”)1, asserting claims, inter alia, seeking damages for fraud, breach of fiduciary duty, aiding and abetting breach of fiduciary duty, and violations of certain rules of the National Association of Securities Dealers (“NASD”) and New York Stock Exchange (“NYSE”). Pending before the Court are: (1) defendants’ motion to dismiss the complaint in its entirety pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure for failure to state a claim for relief; and (2) plaintiffs cross motion pursuant to Rule 15(a)(2) of the Federal Rules of Civil Procedure for leave to amend the complaint. For the reasons set forth below, defendants’ motion is granted and plaintiffs cross motion is denied.

I. BACKGROUND

A. Factual Background2

Plaintiff owned a corporation, New York Medical, Inc. (“NY Medical”), through which he sought to establish an employee stock ownership plan (ESOP) in order to “diversify! ] his personal assets and simultaneously reward[ ] employees of N.Y. Medical.” (Compl., ¶¶ 6, 81). Specifically, plaintiff, “decided to engage in a so-called seller-financed ESOP transaction with leveraged qualified- replacement property (QRP), as defined in Section 1042 of the Internal Revenue Code.” (Compl., ¶ 84).

On November 30, 2000, N.Y. Medical and plaintiff entered into a letter agreement with Citibank, N.A. (“Citibank”), pursuant to which Citibank agreed to lend N.Y. Medical fifteen million dollars ($15,000,000.00) upon N.Y. Medical’s execution of a demand note payable in that amount to Citibank. (Compl., ¶ 85). On that same date: (1) Citibank loaned N.Y. Medical fifteen million dollars ($15,000,-000.00); (2) N.Y. Medical loaned the entire amount of the Citibank loan proceeds to its ESOP; (3) the ESOP used the entire amount of N.Y. Medical’s loan proceeds to purchase four hundred fifty thousand (450,000) shares of N.Y. Medical’s stock from plaintiff; (4) plaintiff used the proceeds from the stock sale to lend N.Y. Medical fifteen million dollars ($15,000,-000.00); and (5) N.Y. Medical used the proceeds of plaintiffs loan to satisfy its obligation under the Citibank demand note. (Compl., ¶ 86). As a result of those transactions, plaintiff did not retain any cash from his sale of stock to the ESOP, but held a note of N.Y. Medical in the amount of fifteen million dollars ($15,000,-000.00) evidencing his loan to that company. (Compl., ¶ 87).

After plaintiffs sale of stock to the ESOP, he “sought to purchase certain QRP in order to defer under Section 1042 of the Internal Revenue Code recognition of any gain that he had realized on the sale of that stock.” (Compl., ¶ 88). Since plaintiff did not retain any cash from his sale of stock to the ESOP, “he was unable to buy that QRP without borrowing the funds to do so.” (Id.) On November 1, 2000, plaintiff, N.Y. Medical and Citibank executed a “Revolving Credit Note (Multiple Advances)” (“the revolving credit note”), pursuant to which Citibank made available to plaintiff a line of credit not exceeding twelve million dollars ($12,000,000.00). (Compl., ¶ 89). According to plaintiff, the line of credit was a recourse loan on which he was allowed to draw during the period from November 1, 2000 to October 31, 2001. (Id.) On that [112]*112same date, (1) plaintiff executed a “General Hypothecation Agreement” (“GHA”), pursuant to which he pledged certain rights to the QRP he intended to purchase with the loan proceeds that he borrowed against the line of credit as security for the line of credit, (Compl., ¶ 90); and (2) N.Y. Medical executed a “General Security Agreement,” pursuant to which it granted a security interest in all of'its assets to Citibank as collateral for its obligations under the revolving credit note. (Compl., ¶ 91). Between November 2, 2000 and November 29, 2001, plaintiff purchased floating rate notes (“FRNs”) as QRP at a total cost of fifteen million dollars ($15,000,000.00). (Id.)

On February 11, 2002, plaintiff and his wife executed the following documents amending the revolving credit note and GHA: (1) an “Amended and Restated Revolving Credit Note (Multiple Advances)” (“amended revolving credit note”), inter alia, increasing the Citibank line of credit to $13.5 million (“the Citibank increased line of credit”), and substituting plaintiffs wife for N.Y. Medical as a borrower thereunder; and (2) an “Amended and Restated General Hypothecation Agreement” (“the amended GHA”). (Compl., ¶ 92). According to plaintiff, he drew upon the Citibank increased line of credit, and used $1.5 million of his own funds, to purchase “$15 million of FRNs,” and pledged those FRNs as security for the Citibank transaction. (Compl., ¶ 93).

Plaintiff alleges that “[i]n proposing a line of credit * * *, Citibank informed him that the use of FRNs as QRP would achieve a result known as ‘zero-cost borrowing’, which was [his] objective.” (Compl., ¶ 95). According to plaintiff, on June 12, 2002, after Citibank failed to provide such “zero-cost borrowing” during 2001 and 2002, he retained Corporate Solutions Group, LLC (“CSG”) “to assist him in negotiating with a different lender a new loan of $13.5 million dollars [sic] that would replace the Citibank increased line of credit.” (Compl., ¶ 95).

On or about August 2002, CSG informed plaintiff about Derivium Capital, LLC (“Derivium”), (Compl., ¶ 96), a limited liability company of which Charles Cathcart (“C. Cathcart”) was a fifty percent (50%) owner and Yuri Debevc and Scott Cathcart (“S. Cathcart”) were each twenty-five percent (25%) owners (collectively, “the Derivium owners”). (Compl., ¶¶ 2, 35). At all relevant times: (1) other entities, including Optech Ltd. (“Optech”), Bancroft Ventures, Ltd. (“Bancroft”), Witco Services Ltd. (“Witco”) and Veridia Solutions LC (“Veridia”) (collectively, “the Derivium alter ego companies”), were wholly owned or controlled by the Derivium owners, (Compl., ¶¶ 3, 35); and (2) Anderson Jr. was an employee, the director of client services and an account executive of Derivium, (Compl., ¶ 9).

According to plaintiff, “Derivium perpetrated a fraudulent securities loan scheme known as the Derivium 90% Securities Loan Program” (“the 90% Loan Program”), (Id.), pursuant to which Derivium “purported to make loans to borrowers worth 90% of the value of their securities.” (Compl., ¶ 36). According to plaintiff, borrowers under the 90% Loan Program “would deposit their securities as collateral for the 90% Loan into accounts at one of several major brokerage houses, including Wachovia * * *, where their securities would purportedly be held and hedged by Derivium using what Derivium purported to be * * * a secret, proprietary hedging strategy. At the end of the loan term, borrowers could pay the loan balance and retrieve their collateral, surrender their collateral in satisfaction of the loan, or renew their loan.” (Id.)

[113]

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Wolfe v. Pugh
E.D. Tennessee, 2022
Derrek Wade Pugh
E.D. Tennessee, 2022
Salameno v. Rawlings
S.D. New York, 2021
Rochlis v. United States
Federal Claims, 2020
Zirvi v. Flatley
S.D. New York, 2020
In Re: Risperdal Litig., Appeal of: Winter, J.
Supreme Court of Pennsylvania, 2019
In Re: Risperdal Litig., Appeal of: Saksek, J.
Supreme Court of Pennsylvania, 2019
Mullen v. Vill. of Painted Post
356 F. Supp. 3d 275 (W.D. New York, 2019)
Harris v. TD Ameritrade Inc.
338 F. Supp. 3d 170 (S.D. Illinois, 2018)
Trisvan v. Heyman
305 F. Supp. 3d 381 (E.D. New York, 2018)
Chuan Wang v. Palmisano
157 F. Supp. 3d 306 (S.D. New York, 2016)
Dechberry v. New York City Fire Department
124 F. Supp. 3d 131 (E.D. New York, 2015)
Wang v. Palmisano
51 F. Supp. 3d 521 (S.D. New York, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
966 F. Supp. 2d 106, 2013 WL 4432383, 2013 U.S. Dist. LEXIS 116149, Counsel Stack Legal Research, https://law.counselstack.com/opinion/landow-v-wachovia-securities-llc-nyed-2013.